Clinical Trials Logo

Palliative Radiotherapy clinical trials

View clinical trials related to Palliative Radiotherapy.

Filter by:
  • None
  • Page 1

NCT ID: NCT04658537 Recruiting - Clinical trials for Radiotherapy, Intensity-Modulated

Advanced Techniques for Single-fraction Palliative Radiotherapy Versus ASPIRE-single

ASPIRE single
Start date: June 29, 2021
Phase: N/A
Study type: Interventional

One third of patients treated in the radiation oncology departments are treated with palliative intent. These patients can be unwell due to their advanced disease and suffering from pain and other symptoms related to metastases. Radiation therapy (RT) has an important role in the symptomatic relief and improvement in the quality of life (QoL) for these patients.The aim of the study is to determine if escalated single fraction palliative radiotherapy using intensity-modulated techniques results in a prolonged duration of benefit for patients otherwise suitable for standard single fraction radiotherapy.

NCT ID: NCT04649125 Recruiting - Clinical trials for Palliative Radiotherapy

Advanced Techniques For Single-fraction Palliative Radiotherapy Versus Standard Multi Fraction Radiation

ASPIRE_Multi
Start date: May 31, 2021
Phase: N/A
Study type: Interventional

The aim of the study is to determine if single fraction dose escalated palliative radiotherapy results in a prolonged duration of benefit for patients otherwise suitable for Multifraction (5-10#) palliative radiation. The primary endpointis to determine the percentage of patients who have achieved a substantial benefit from palliative radiotherapy and have not redeveloped symptoms by 12 months post treatment

NCT ID: NCT04133415 Completed - Cancer Clinical Trials

Palliative Lattice Stereotactic Body Radiotherapy (SBRT)

Start date: October 31, 2019
Phase: N/A
Study type: Interventional

Standard palliative radiotherapy regimens may provide limited durability of response in large tumors. Thus, there is a clinical need for a new approach. The Lattice SBRT approach will deliver 20 Gy in 5 fractions with partial volume simultaneous integrated boosts to 66.7 Gy. This is hypothesized to improve symptom response, local control, and better prime the tumor microenvironment for immune response compared with standard palliative radiotherapy doses. It is also hypothesized that this will be associated with less toxicity than the traditional homogenous SBRT plan delivered to a large tumor. Blood will be collected before and after Lattice SBRT for evaluation of the peripheral blood immune microenvironment.